Dados do Trabalho

Título

CORRELAÇAO DE VARIAVEIS CLINICO-PATOLOGICAS COM A RESPOSTA PATOLOGICA COMPLETA A QUIMIOTERAPIA NEOADJUVANTE NO CANCER DE MAMA TRIPLO NEGATIVO

Título em Inglês

CORRELATION OF CLINICAL-PATHOLOGICAL VARIABLES WITH THE PATHOLOGIC COMPLETE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER.

Introdução

The triple-negative breast cancer (TNBC) is one of the most aggressive types of breast cancer, about 15 to 20% of invasive breast tumors. Refers to those tumors that in immunohistochemistry do not express homone receptors and epidermal growth factor type 2 (cerbB2). This tumor phenotype does not have many therapeutic options, beyond standart chemotherapy, and this context, the evidence of some markers of this type of tumor may contribute to the discovery of more effective therapies.

Relato de caso

Objectives: The aim of this study is to define predictive and prognostic factors in TNBC that could be related with a pathologic complete response after neoadjuvant chemotherapy treatment. Methods: Descriptive and retrospective study, case series type, in women with TNBC who underwent neoadjuvant chemotherapy and surgery at the Mastology Service of Maternidade Escola Assis Chateaubriand – Brazil - from May 2015 to June 2020. The statistical analysis was performed considering the 5% significance level. Results: In the total of 108 women, only 47 were included in the study, with median age of 49 years (+14 years); about 30 (42.6%) had a family history of breast cancer in first or second degree relatives. About 44 (93.6%) cases were classified as invasive ductal tumor and grade II or III; the value of Ki67 greater than 14% was evidenced in 46 (97.9%) women and 26 (55.3%) had clinical stage III. Pathological complete response to chemotherapy was evidenced in 16 (34%) cases, partial response in 13 (27.7%) and no response in 18 (38.3%) cases, in the latter cases corresponded those who had stable or progression disease. There was recurrence in 13 (27,7%) women, about 8 distant metastasis, with the lung the most frequent site of metastasis followed by the brain. Eleven patients, about 23,4%, died. In the survival analysis of the studied population, the overall survival was 56,6 months and disease-free survival was 19.4 months. No association was observed in the study between the outcome pathological complete response to neoadjuvant chemotherapy and anatomopathological characteristics of the tumor. Conclusion: The results of this study did not show statistical significance to determine the possible predictive and prognostic factors for obtaining a complete clinical response to TNBC in a public reference service in the treatment of breast cancer, where there is no genetic signature, PDL1 status or access to differentiated treatment for such a heterogeneous tumor profile; this demonstrates a need for further studies to understand this disease and greater accessibility to high-cost exams and more effective treatments.

Palavras Chave

PATHOLOGIC COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; TRIPLE-NEGATIVE BREAST CANCER.

Área

TUMOR CELL, MOLECULAR BIOLOGY, PREDICTIVE AND PROGNOSTIC FACTORS - Tumor cell, molecular biology, predictive and prognostic factors – other